Prognostic role of braf mutations in colorectal cancer liver metastases

Emmanouil Pikoulis; Georgios A. Margonis; Nikolaos Andreatos; Kazunari Sasaki; Anastasios Angelou; Georgios Polychronidis; Anastasia Pikouli; Elena Riza; Timothy M. Pawlik; Efstathios Antoniou

doi:10.21873/anticanres.11040

Prognostic role of braf mutations in colorectal cancer liver metastases

Emmanouil Pikoulis, Georgios A. Margonis, Nikolaos Andreatos, Kazunari Sasaki, Anastasios Angelou, Georgios Polychronidis, Anastasia Pikouli, Elena Riza, Timothy M. Pawlik, Efstathios Antoniou

School of Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.

Original language	English (US)
Pages (from-to)	4805-4811
Number of pages	7
Journal	Anticancer Research
Volume	36
Issue number	9
DOIs	https://doi.org/10.21873/anticanres.11040
State	Published - Sep 1 2016

Keywords

BRAF
CRLM
Prognosis

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.21873/anticanres.11040

Cite this

@article{77abb3f340574ec6afcca11911a52469,

title = "Prognostic role of braf mutations in colorectal cancer liver metastases",

abstract = "Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.",

keywords = "BRAF, CRLM, Prognosis",

author = "Emmanouil Pikoulis and Margonis, {Georgios A.} and Nikolaos Andreatos and Kazunari Sasaki and Anastasios Angelou and Georgios Polychronidis and Anastasia Pikouli and Elena Riza and Pawlik, {Timothy M.} and Efstathios Antoniou",

year = "2016",

month = sep,

day = "1",

doi = "10.21873/anticanres.11040",

language = "English (US)",

volume = "36",

pages = "4805--4811",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

TY - JOUR

T1 - Prognostic role of braf mutations in colorectal cancer liver metastases

AU - Pikoulis, Emmanouil

AU - Margonis, Georgios A.

AU - Andreatos, Nikolaos

AU - Sasaki, Kazunari

AU - Angelou, Anastasios

AU - Polychronidis, Georgios

AU - Pikouli, Anastasia

AU - Riza, Elena

AU - Pawlik, Timothy M.

AU - Antoniou, Efstathios

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.

AB - Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.

KW - BRAF

KW - CRLM

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84991573148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991573148&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11040

DO - 10.21873/anticanres.11040

M3 - Article

AN - SCOPUS:84991573148

SN - 0250-7005

VL - 36

SP - 4805

EP - 4811

JO - Anticancer Research

JF - Anticancer Research

IS - 9

ER -

Prognostic role of braf mutations in colorectal cancer liver metastases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this